Ricky Kellenberger, DO
Family Medicine · Fort Scott, KSNPI 1700864568
Payments from drug & device makers
Across 106 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$217
- Otsuka America Pharmaceutical, Inc.$198
- Pfizer$159
- Indivior Inc.$155
- AbbVie$140
- Lilly USA, LLC$110
- plus $808 from 24 others
What the payments were for
- Food & beverage$1,786100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $217 |
| Otsuka America Pharmaceutical, Inc. | 11 | $198 |
| Pfizer | 10 | $159 |
| Indivior Inc. | 10 | $155 |
| AbbVie | 8 | $140 |
| Lilly USA, LLC | 7 | $110 |
| Novo Nordisk | 4 | $75 |
| Bayer | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Collegium Pharmaceutical, Inc. | 3 | $56 |
| Merck | 3 | $48 |
| Novartis | 3 | $48 |
| Amgen | 3 | $45 |
| GSK | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Boehringer Ingelheim | 2 | $27 |
| Redhill Biopharma Inc. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Sanofi | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Orexo US, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Radius Health, Inc. | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,786 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 177 | $117,014 |
| OzempicSemaglutide | 66 | $64,451 |
| FarxigaDapagliflozin Propanediol | 72 | $51,398 |
| LinzessLinaclotide | 52 | $39,596 |
| Buprenorphine | 81 | $31,608 |
| MounjaroTirzepatide | 30 | $30,971 |
| RybelsusSemaglutide | 30 | $30,515 |
| VraylarCariprazine Hcl | 19 | $29,164 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $28,892 |
| JardianceEmpagliflozin | 22 | $25,957 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 53 | $25,698 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $19,915 |
| SymbicortBudesonide/Formoterol Fumarate | 78 | $19,185 |
| XareltoRivaroxaban | 32 | $18,989 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $15,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $117,014177 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $217 | $99,475188 claims |
| Novo NordiskOzempic, Rybelsus | $75 | $94,96796 claims |
| AbbVieLinzess, Vraylar | $140 | $68,76071 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $27 | $67,19793 claims |
| GSKIncruse Ellipta, Trelegy Ellipta, Anoro Ellipta | $41 | $42,20377 claims |
| Lilly USA, LLCMounjaro, Trulicity | $110 | $41,74941 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $14,76226 claims |
| NovartisEntresto | $48 | $10,87911 claims |
| MerckBelsomra | $48 | $10,15731 claims |
| Redhill Biopharma Inc.Movantik | $27 | $10,13224 claims |
| BayerKerendia | $74 | $8,32413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Fort Scott
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.